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In order to assess the level of polio virus with natural recombinant genome and wild polio virus 
circulating in the environment of healthy children aged 0 to 5 years in Abidjan, 130 polio viruses made 
up of 26 polio type 1, 55 type 2 and 49 type 3 were identified by neutralisation test with monoclonal 
antibodies and restriction fragment length polymorphism (RFLP) targeting the VP1 and 3D1 gene. Four 
wild non Sabin-like (NSL) strains (3.1%): one type 2 and three type 3 were identified in non vaccinated 
children. One hundred and six (81.5%) isolates were Sabin-like, 20 (15.4%) were recombinant with the 
following polio virus profiles: 2 Sabin-like type 1/type 2, 3 Sabin-like type 3/type 1, 11 Sabin-like type 
3/type 2 and one polio virus type 3 NSL/Sabin-like type 3. Intertypic vaccine/vaccine or vaccine/wild 
strain recombinant polio virus circulating among healthy children rate was high and suggested the 
need for a molecular surveillance of vaccine strains. Oral Polio Vaccine (OPV) strains are well-known to 
revert to pathogenicity in vaccines. Therefore, the long term excretion of pathogenic OPV derived 
strains by some vaccinees needs to be considered quite seriously. It therefore suggested that all polio 
virus isolated from acute flaccid paralysis (AFP) be analyzed by restriction fragment length 
polymorphism and sequencing of the viral genome. 
 





Côte d'Ivoire has subscribed to the eradication paralytic 
poliomyelitis program initiated by World Health Assembly 
(Resolution WHA 41.28). Oral Polio Vaccine (OPV) was 
successfully used to control paralytic poliomyelitis in 
temperate climates and some subtropical region of the 
world, especially the Americas (EPI/PAHO, 1993; EPI, 
1994). 
Vaccination campaigns, routine immunization and 
active surveillance programs are needed before the 
ultimate goal of eradication is achieved. However these 
vaccine strains raise some problems which can 
compromise the eradication of poliomyelitis. Mutations 
and recombination occur frequently with vaccine strains, 
especially with the less stable types 2 and 3 polio virus, 
upon replication in the human intestine (Pallansch and 
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to neurovirulence. Some cases of acute flaccid paralysis, 
vaccine associated paralytic poliomyelitis  (VAPP) have 
been described with vaccine strains as reported by 
Furione et al. (1993) and Georgescu et al. (1995). There 
is little or no information on the survival rate of the OPV 
viruses in circulation in Cote d’Ivoire after vaccination. It 
is therefore important to evaluate the rate of 
recontamination of the population after mass vaccination 
campaigns, and assess the risk associated with mutation 
or recombination of the vaccine strains as observed in 
earlier findings by Fine and Carneiro (1999). 
Before setting up the acute flaccid paralysis (AFP) 
active surveillance in 1997, studies were held to 
determine the level of wild polio virus circulating among 
children, in rural or urban areas during which period 
many polio viruses were isolated from vaccinated and 
non vaccinated children in Cote d’Ivoire.  
This study is therefore aimed at reporting the level of 
recombination and wild polio virus circulating among 
healthy children aged 0 to 5 years in Abidjan in 1996. 




                     Table 1. Vaccinal status of Poliovirus carriers according to the period of stool collection.  
 
 0 OPV dose 1 OPV dose 2 OPV doses 3 OPV doses 















 P0 P1 P2 P3 
Virus (n = 130) 
Newborns  
Contacts  
 Polio     NPE 
   0            0 
    -             - 
  Polio     NPE 
66 0 
17          12 
   Polio     NPE 
15          9 
 11        11 
 Polio    NPE 
21        11    
 -           - 
 
OPV = Oral Poliovirus Vaccine 
P0 = samples collected before OPV 
P1 = samples collected after 1st dose of OPV 
P2 = samples collected after 2nd dose of OPV 
P3 = samples collected after 3rd dose of OPV 




MATERIAL AND METHODS 
 
Population and stool collection  
 
The study was udertaken in a suburban environment in Abidjan. 
One hundred and fourty-five newborns were recruited on the basis 
of the following criteria: delivery in a maternity center, and 
possibility to monitor the mother and child, and others in the family. 
Two-hundred and fifty-two contacts made up of brothers, sisters 
and children living in the commune yard in a cohorte of 3 to 5 per 
family were enrolled. 
Between March and August 1996, samples of freshly produced 
stools were collected from each child at different periods. For the 
newborns, stools were collected before OPV and 8 days after each 
OPV dose according to the immunization timetable. For the 
contacts, stools were collected during the second and third 
collecting periods with the newborns. The samples were 
accompanied by information forms and were forwarded to the 
Enterovirus Laboratory in Institute Pasteur Cote d'Ivoire (IPCI), in 
iceboxes, at 0° and + 4°C . Samples were stored at –20°C until 
ready for use. 
 
 
Isolation and identification  
 
Stool samples were treated for virus isolation and identication 
according to the protocol recommended by World Health 
Organisation (WHO 1990). Briefly described, stools were extracted 
with chloroform and inoculated into Hep-2 and RD cells and typed 
by sero-neutralization. The isolation and identification of the isolates 
were carried out at IPCI Enterovirus Laboratory.  
Intratypic differentiation (ITD) was done by monoclonal 
antibodies (Mab) and by reverse transcriptase polymerase chain 
reaction (RT-PCR) followed by restriction fragment length 
polymorphism (RFLP) according to the modified version of Balanant 
et al. (1991) at the Reference Regional Polio Laboratory, Pasteur 
institute in Bangui. The PCR targeted two regions:  
 
1. Capsid's VP1 polypeptide gene, a sequence of 472 to 480 
nucleotides according to the type of polio virus, using the 
“downstream” primer UC1 (5'-GAATTCCATGTCCAAATCTAGA-
3’) and the “upstream” primer UG1 (5'-GAATTCCATGTCCAAAT 
CTAGA-3’).  
2. Polymerase 3D1 region gene, a sequence of 431 nucleotids 
(6086-6376) amplified with the “downstream” primer UC12 (5'- 
GAATTCCATGTCCAAATCTAGA-3’) and “upstream” primer UG7 
(5'TTTGAAGGGGTGAAGGAACCAGC-3) with a view to 
highlighting the genomic recombinations.  
 
Strain-specific restriction profiles were generated using three 
restriction enzymes, HaeIII, HpaII and DdeI for RFLP-1, and HaeIII, 
RsaI and XbaI for RFLP-3D1 as reproted by Guillot et al. (2000), 
with 1.5% agarose for the electrophoresis. The reagents used, 
polyclonal and monoclonal antibodies, primers and restriction 
enzymes for the RFLP test were provided by the WHO Reference 
and Research Center for Poliomyelitis of the Paris Institute Pasteur 





The EPI/INFO software was used for the statistical study of the 
results obtained. The Pearson's chi square tests with corrections by 
YATES were used to compare the populations that were surveyed 








A total of 918 samples were collected out of which 173 
(18.8%) enterovirus strains were isolated. These 
consisted of 130 polio virus (75.1%) and 43 (24.9%) non 
polio-enterovirus (NPEV) from 121 children. Of the 130 
polio viruses, 26 (20%) were type 1, 55 (43.3%) type 2 
and 49 (37.7%) were type 3. Approxymatly 78.5% of the 
polio virus were isolated from the newborns and 21.5% 







Intratypic differentiation of the 130 polio viruses were 
determined using the monoclonal antibodies technique. 
Five (3.8%)  wild or non-Sabin-like (NSL) strains (one 
type 1 and 4 type 3) were isolated from the contacts, 
three of which have not received any previous OPV dose, 




Characterization by RT-PCR/RFLP 
 
All the 130 polio virus isolates were analyzed by the RT-
RFLP method. Only 4 of the 5 NSL were identified as 
NSL by the RT-PCR-RFLP, and were made up of one 
type 1 and Poliovirus type 2 and 3 Poliovirus type 3 (not 
shown). The RT-PCR-RFLP identified 106 as SL strains. 
Nineteen SL and one NSL virus showed recombinant 
profiles with the RFLP-3D1 region. Sabin-like type 3 
strains carried more recombinations (13/20, 65%), than 
type 2 (3/20) and type 1 (2/20). One NSL type 3, 
previously identified by the monoclonal antibodies 
technique turned out to be a recombinant strain wild 
Poliovirus 3/Sabin-like 3. The distribution of the 
recombinants is shown in Table 2. The results of both the 
ITD by monoclonal antibodies and RFLP test showed that 
81.5% were vaccine strains, 15.4% recombinant strains 
while 3.1% were wild strains.  
 
 





(n = 4) 
Recombinants 
(n = 20) 
24 Polio 1 
51 Polio 2 
31 Polio 3 
 
1 Polio 2 





1 Polio 3 NSL/S3 
 
NSL = non Sabin-like 
S1 = Poliovirus type 1 Sabin-like 
S2 = Poliovirus type 2 Sabin-like 




Comparison between ITD by monoclonal antibodies 
and RT-PCR/RFLP 
 
One hundred and twenty-five polio virus isolates were 
identified by monoclonal antibodies as SL type 1 (26 
strains), type 2 (54 strains) and type 3 (46 strains) and 5 
as NSL.  RFLP identified 24 as SL type 1, 51 SL type 2 
and 31 SL type 3. In the same manner the RFLP 
identified 4 NSL and 20 recombinant strains profiles. The 
RFLP confirmed the serotype and gave complementary 
information by pointing out the recombinant strains.  






In this study we have attempted to determine the rate of 
recombinant and wild polio virus circulating among 
vaccinated and non-vaccinated children in Abidjan. 
Children carrying poliovirus were newborns aged 2 
months to 4 months, a period of full vaccinal activity, 
hence the high number of excreted vaccinal strains as 
compared to 1 to 6 years among the contacts. As shown 
in Table I, on the basis of the vaccination cards available, 
most of the contacts found positive had not received OPV 
while only 8 of them have received between the ages of 6 
months and 4 years. All the newborns recruted received 
OPV. Three NSL strains were isolated from non 
immunized children.   
In this study, we have found a carrier rate of 14.2% 
among children in Abidjan. This is significantly different 
from the rate obtained by Gershy-Damet et al. (1986) in 
Abidjan when he found only 8% among children aged 6 
to 8 years old (p<0,001). This difference could be 
explained by the fact that in our study only contacts of 
vaccinees were enrolled. The majority of isolates were 
vaccine serotype 2 (49%). This is in aggrement with the 
finding of Krugman et al. (1960). The administration of 
trivalent vaccine is indeed followed mainly by excretion 
containing serotype 2 as reported by Fine and Carneiro 
(1999). However, the persistence of excretion after the 3rd 
dose raises questions as to the future of vaccinal strains. 
Among the strains analyzed, 81.5 % were of vaccinal 
origin, 3.1% were wild Poliovirus strains and 15.4% were 
recombinants. Natural modifications in the genome is a 
normal evolution for most RNA genomic viruses out of 
which polio virus is one. This property is more 
pronounced especially among the vaccine strains. The 
genome of the vaccine strains can carry out mutation and 
recombination processes, and those recombinant strains 
can be responsible for acute flaccid paralysis. Although 
the biological significance of frequent occurence of 
recombinants among field isolates of vaccine-related 
strains was discussed by Lipskaya et al. (1991), many 
authors (Beletskaia et al., 2002; Furione et al., 1993; 
Friedrich et al., 1996) have reported recombinant strains 
isolated from vaccine-associated paralytic poliomyelitis 
cases, some with a high proportion of 50% (Guillot et al., 
2000).  
The recombinant vaccine strains should be investigated 
on molecular aspects, sequencing the VP1 capsid and 
RNA polymerase regions. Intertypic vaccine/vaccine or 
vaccine/non recombinant Poliovirus rate 15.4% obtained 
in this study seemed high among these apparently 
healthy children, particulary in those without a strong 
immunity during the immunization period or even after the 
three OPV doses. Serotype 3 is considered as the least 
immunogenic among the vaccinal strains as shown by 
many serological studies (Akoua et al., 1995; Sabin, 
1984). It would have been advisable to study the immune 
status of all the children who excreted Poliovirus after  




three doses of OPV. An incomplete or absence of 
immune response after the three OPV doses might 
explain an unapparent infection by a vaccinal or wild 
strain.  
Recombinant polio virus strains excretion and 
circulation among non or insufficiently immunized 
populations might constitute a risk for the Polio 
eradication program because of potential epidemics of 
poliomyelitis that may occur. It therefore seems important 
to get high immunization coverages in the first year of live 
(0-11 months), specially in the developping  countries 
because of the contact with other eterovirus infection in 
early life.   In 75% cases of the recombinant strains, 
Sabin-like type 3 was implicated, 20% with type 2 and 
10% with type 1. It is known that type 3 vaccine strains 
contains less attenuated mutations compared with the 
type 1 and type 2 strains of OPV. Moreover, OPV strains 
are well-known to revert to pathogenicity in vaccinees, 
therefore the long term excretion of pathogenic OPV 
derived strains by vaccinees needs to be considered 
quite seriously. 
Despite immunization by OPV, wild polio virus were 
circulating among children but at a lower level. This fact 
justifies the vast immunization campaigns, in form of 
national immunization days (NIDs) in Cote d’Ivoire since 
1997. Wild polio virus circulation among healthy children 
immunized with OPV is also reported by Andrianarivelo et 
al. (1999) in Antananarivo, Madagascar. This situation is 
common if the immunization coverage is low, and the 
titres of specific antibodies against polio virus are 
insufficient to protect against new Poliovirus infections. 
Two of the 5 children carrying a wild virus strains had 
received one dose recommended at 1 and 2 months old. 
Their immunity did not prevent intestinal carriage of wild 
polio virus strains. 
From the virological point of view, the RT-PCR/RFLP 
technique allowed a better intratypic discrimination 
because it revealed the structural modifications of the 
viral genomes which were not identified by the 
monoclonal antibodies as earlier described by Crainic 
and Kew (1993). However the use of RFLP tests has 
made it possible to discover recombinations. Nineteen 
recombinant strains and the NSL/SL strain were identified 
as SL and NSL using monoclonal antibodies. The study 
relating to these strains will be completed by the analysis 
of the nucleotide sequences of the amplified VP1 region 
to determine the nature of the changes observed in 
RFLP. 
Intertypic vaccine/vaccine or vaccine/wild strain 
recombinant Poliovirus circulation among healthy children 
is frequent and suggest a molecular surveillance. Routine 
and mass immunization campaigns provide a lot of 
vaccine strains in circulation. These campaigns are 
usefull to eradicate wild Poliovirus but there is a risk of 
spreading of the genetically modified OPV strains which 
could be associated with illnesses such as paralytic 





isolated from acute flaccid paralysis cases should be 
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